



BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------	------------	------------------	-------------------

## Lupin in Alliance with Natco to commercialize generic equivalent of Tykerb<sup>®</sup> Tablets

**Mumbai, June 23, 2011:** Lupin Ltd. and Natco Pharma announced today an alliance to jointly commercialize generic equivalent of Glaxo's Tykerb<sup>®</sup> (Lapatinib ditosylate) tablets. Natco had filed an abbreviated new drug application (ANDA) seeking US FDA's approval for marketing generic equivalent of Tykerb<sup>®</sup> 250 mg tablets.

Natco and Lupin believe that they are first-to-file an ANDA containing a Paragraph IV certification for Lapatinib. Tykerb<sup>®</sup> had sales of USD 113.6 Million as of March 2011 (IMS).

### About Lupin Limited

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant presence in Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.

Today, Lupin is the 5th largest and the fastest growing Top 5 generics player in the U.S. (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS)

For the financial year ended March 2011, Lupin's Consolidated Sales and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million respectively. Please visit <http://www.lupinworld.com> for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

### **For further information please contact:**

Shamsher Gorawara

Lupin Limited:

Ph: +91 98 20 338 555

Email: [shamshergorawara@lupinpharma.com](mailto:shamshergorawara@lupinpharma.com)

*Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:*

*This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.*